Natasha Strande, PhD, DABMGG, FACMG is an Senior Associate Consultant within the Division of Laboratory Genetics and Genomics at the Mayo Clinic. She is board-certified in Laboratory Genetics and Genomics by the American Board of Medical Genetics and Genomics (ABMGG) and has extensive experience analyzing exome data and evaluating clinically important genomic variants. She has contributed to multiple collaborative research projects, such as the Clinical Genome Resource, where she was integral in developing a framework to evaluate the clinical validity of gene-disease relationships and continues to be actively involved in optimizing variant interpretation guidelines across different disease areas. In her current role at the Mayo Clinic she analyzes and interprets exploratory genome-scale genetic test results. In her previous position at Geisinger as Clinical Laboratory Director for the Precision Health Program, she oversaw the biobanking for the MyCode Community Health Initiative research project which served to identify and disclose clinically actionable variants to MyCode participants. Prior to her role at Geisinger, Dr. Strande completed her doctoral and post-doctoral work at the University of North Carolina (UNC) where she received her PhD in Biochemistry and Biophysics and completed the ABMGG Laboratory Genetics and Genomics fellowship. During her time at UNC Dr. Strande was involved in multiple different clinical research projects focused on examining how exome sequencing efforts can be implemented into the clinical laboratory. As a clinical laboratory geneticist, she is interested in rare hereditary diseases and passionate about improving patient care by optimizing and standardizing molecular analysis guidelines and approaches. As co-chair of the ACMG Workforce Development and Optimization workgroup she is invested in growing the genetics workforce to make genetic testing more accessible to all patients.